항간질약 시장 규모, 점유율, 성장률 및 세계 업계 분석, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of antiepileptic drugs (AED) Market

The global antiepileptic drugs (AED) market was valued at USD 17.82 billion in 2025 and is projected to grow from USD 18.57 billion in 2026 to USD 27.57 billion by 2034, exhibiting a CAGR of 5.10% during the forecast period. North America dominated the global market with a 48.40% market share in 2025, driven by the high prevalence of epilepsy, favorable reimbursement policies, strong research and development investments, and continuous product approvals. Increasing awareness of neurological disorders, expanding access to healthcare, and the development of safer and more effective therapies are expected to support long-term market growth.

Epilepsy is one of the most common neurological disorders worldwide, affecting nearly 50 million people, according to the World Health Organization (WHO). The disease causes recurrent seizures that can significantly affect patients' quality of life. Rising diagnosis rates, improved healthcare infrastructure, and growing demand for advanced therapies are encouraging pharmaceutical companies to introduce innovative antiepileptic drugs with improved safety profiles and fewer adverse effects. Although the COVID-19 pandemic temporarily disrupted neurological care and drug demand, the market has recovered as patient visits and treatment rates returned to normal.

Growing Development of Third-Generation AEDs Emerging as a Key Market Trend

One of the most significant trends in the antiepileptic drugs market is the increasing focus on developing third-generation antiepileptic drugs. Pharmaceutical companies are investing heavily in research to introduce therapies that provide better seizure control with reduced side effects compared to earlier drug generations.

Patent expirations of several second-generation drugs have created opportunities for manufacturers to launch both innovative therapies and cost-effective generic alternatives. Continuous regulatory approvals are also supporting market expansion. For instance, newer formulations of perampanel have been introduced to improve treatment options for patients who are temporarily unable to take oral medications. Such product innovations are expected to strengthen the competitive landscape throughout the forecast period.

Rising Prevalence of Epilepsy and Product Approvals Driving Market Growth

The increasing global burden of epilepsy remains the primary growth driver for the antiepileptic drugs market. Despite the availability of numerous medications, a considerable proportion of patients continue to experience drug resistance or intolerable side effects, creating demand for next-generation therapies.

Pharmaceutical companies are focusing on developing target-specific treatments through advanced clinical research and regulatory approvals. Increasing approvals from health authorities are expanding treatment options for patients suffering from partial-onset seizures and other forms of epilepsy. Additionally, growing investments by governments and healthcare organizations to improve neurological care are supporting wider adoption of AED therapies across developed and emerging economies.

Drug Supply Challenges May Restrict Market Expansion

Despite positive market prospects, shortages in the supply of antiepileptic drugs continue to present a significant challenge. Disruptions in pharmaceutical supply chains and stockpiling of essential medicines have resulted in limited availability of certain epilepsy medications in several countries.

Limited awareness regarding epilepsy treatment, especially in low- and middle-income countries, further restricts medication adoption. In addition, delays in diagnosis and inadequate healthcare access continue to prevent many patients from receiving appropriate long-term treatment, slowing overall market growth.

Second-Generation Drugs Continue to Lead the Market

Based on drug generation, the second-generation drugs segment is expected to account for the largest market share of 39.87% in 2026. These medications remain widely prescribed due to their proven effectiveness, improved safety profiles, and broad clinical acceptance. Although some leading brands have experienced patent expiration, continued demand for these therapies and the availability of generic versions continue to support segment growth.

The third-generation drugs segment is projected to register the fastest growth during the forecast period owing to their broader therapeutic range, improved efficacy, and lower incidence of adverse effects. Meanwhile, first-generation drugs continue to maintain an important role in epilepsy management, particularly in cost-sensitive healthcare systems.

Hospital Pharmacies Dominate Distribution Channel

By distribution channel, hospital pharmacies are projected to hold the largest market share of 50.70% in 2026. The dominance of this segment is attributed to the increasing number of epilepsy patients receiving treatment in hospitals equipped with specialized neurology departments, advanced diagnostic facilities, and favorable reimbursement systems.

Retail pharmacies continue to account for a significant share due to easy accessibility of epilepsy medications. Meanwhile, online pharmacies are expected to witness the fastest growth as telemedicine services, digital healthcare platforms, and home delivery of prescription medicines become increasingly popular across both developed and emerging markets.

North America Remains the Largest Regional Market

North America generated USD 8.63 billion in 2025 and is projected to reach USD 9.00 billion in 2026, maintaining its leadership position due to advanced healthcare infrastructure, higher diagnosis rates, continuous drug innovation, and favorable reimbursement policies. The U.S. market alone is expected to reach USD 7.27 billion by 2026, supported by increasing FDA approvals and growing awareness initiatives.

Europe accounted for USD 4.18 billion in 2025 and is projected to reach USD 4.37 billion in 2026, driven by rising regulatory approvals and expanding access to advanced epilepsy treatments. Asia Pacific reached USD 2.97 billion in 2025 and is expected to grow to USD 3.11 billion in 2026, supported by increasing disease prevalence, improving healthcare infrastructure, and expanding treatment accessibility in countries such as China, India, and Japan. Latin America and the Middle East & Africa are also expected to witness steady growth due to ongoing healthcare improvements and increasing awareness of epilepsy management.

Competitive Landscape Strengthened by Innovation and Strategic Investments

The global antiepileptic drugs market is highly competitive, with leading pharmaceutical companies focusing on product innovation, clinical research, regulatory approvals, and expansion of their neurological treatment portfolios. Major market participants include Pfizer Inc., UCB S.A., GSK plc., H. Lundbeck A/S, Eisai Co., Ltd., Sanofi, Sunovion Pharmaceuticals Inc., and Jazz Pharmaceuticals, Inc.

These companies continue to invest in next-generation epilepsy therapies, generic drug development, and global expansion strategies to strengthen their competitive positions. Ongoing clinical trials and increasing regulatory approvals are expected to introduce more effective treatment options during the forecast period.

Conclusion

The global antiepileptic drugs (AED) market is expected to witness steady growth from 2026 to 2034, supported by the rising prevalence of epilepsy, continuous development of advanced therapies, increasing regulatory approvals, and strong government support for neurological healthcare. Although medicine shortages and treatment accessibility remain ongoing challenges, continued pharmaceutical innovation, expanding healthcare infrastructure, and growing awareness of epilepsy management are expected to sustain market growth. As manufacturers introduce safer and more effective third-generation therapies, the global AED market is well positioned for long-term expansion through 2034.

Segmentation By Drug Generation

• First Generation
• Second Generation
• Third Generation

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Generation, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Epilepsy, By Key Countries/ Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Pipeline Analysis
• 4.4. Overview of Challenges Faced in the Antiepileptic Drugs Market
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 5.1.1. First Generation
  • 5.1.2. Second Generation
  • 5.1.3. Third Generation
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Retail Pharmacies
  • 5.2.3. Online Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 6.1.1. First Generation
  • 6.1.2. Second Generation
  • 6.1.3. Third Generation
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Retail Pharmacies
  • 6.2.3. Online Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 7.1.1. First Generation
  • 7.1.2. Second Generation
  • 7.1.3. Third Generation
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
  • 7.2.3. Online Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 8.1.1. First Generation
  • 8.1.2. Second Generation
  • 8.1.3. Third Generation
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 9.1.1. First Generation
  • 9.1.2. Second Generation
  • 9.1.3. Third Generation
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Retail Pharmacies
  • 9.2.3. Online Pharmacies
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 10.1.1. First Generation
  • 10.1.2. Second Generation
  • 10.1.3. Third Generation
• 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.2.1. Hospital Pharmacies
  • 10.2.2. Retail Pharmacies
  • 10.2.3. Online Pharmacies
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. UCB S.A.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. GSK plc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. H. Lundbeck A/S
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Eisai Co., Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Sanofi
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Sunovion Pharmaceuticals Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Jazz Pharmaceuticals, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)